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Schisandra polysaccharide inhibits hepatic
lipid accumulation by downregulating
expression of SREBPs in NAFLD mice
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Abstract
Background: Hepatoprotective effects of Chinese herbal medicine Schisandra Chinensis (Schisandra) have been
widely investigated. However, most studies were focused on its lignan extracts. We investigated the effects of
Schisandra polysaccharide (SCP) in a mouse model of non-alcoholic fatty liver disease (NAFLD), and studied its
effect on sterol regulatory element binding proteins (SREBPs) and the related genes.
Methods: The mouse model of NAFLD was established by feeding mice with a high-fat diet for 16 weeks. Effect
of SCP-treatment (100 mg/kg, once daily for 12 weeks) on biochemical parameters and liver histopathology was
assessed. Relative levels of sterol regulatory element-binding proteins (SREBPs) and their gene expressions were
determined by quantitative real-time polymerase chain reaction and Western Blot.
Results: SCP significantly reduced the liver index by 12.0%. Serum levels of triglycerides (TG), total cholesterol (TC),
low-density lipoprotein cholesterol, alanine aminotransferase and aspartate aminotransferase were decreased
by 31.3, 28.3, 42.8, 20.1 and 15.5%, respectively. Serum high-density lipoprotein cholesterol was increased by
26.9%. Further, SCP lowered hepatic TC and TG content by 27.0% and 28.3%, respectively, and alleviated fatty
degeneration and necrosis of liver cells. A significant downregulation of mRNA and protein expressions of
hepatic lipogenesis genes, SREBP-1c, fatty acid synthase and acetyl-CoA carboxylase, and the mRNA expression
of liver X receptor α (LXRα) was observed in NAFLD mice treated with SCP. SCP also significantly reduced the
hepatic expression of SREBP-2 and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR).
Conclusion: These findings demonstrate the hepatoprotective effects of SCP in a mouse model of NAFLD; the effects
may be mediated via downregulation of LXRα/SREBP-1c/FAS/ACC and SREBP-2/HMGCR signaling pathways in the liver.
Keywords: Schisandra chinensis (Schisandra), Polysaccharide, Nonalcoholic fatty liver disease (NAFLD), Sterol regulatory
element-binding proteins (SREBPs)
Background
Non-alcoholic fatty liver disease (NAFLD) is one of the
most common precursors of chronic liver diseases (such
as hepatic fibrosis and liver cancer), and metabolic disor-
ders such as obesity, type 2 diabetes, and atherosclerosis
[1, 2]. In recent years, the incidence of NAFLD has dra-
matically increased, with an approximate incidence of
about 20% in general population, and > 60% in patients
with obesity and type 2 diabetes [3]. Though the patho-
genesis of NAFLD is not completely understood, disor-
dered lipid metabolism is considered a key factor. Apart
from interventions such as diet and exercise, no pharma-
ceutical agents are currently available for the treatment
of NAFLD. Therefore, studies on key factors that regu-
late lipid metabolism in the liver, with the aim to dis-
cover novel drug targets for the prevention and
treatment of NAFLD are being carried out.
Sterol regulatory element binding proteins (SREBPs) are
transcription factors that regulate the biosynthesis of
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cholesterol, fatty acids, triglycerides, and the differentiation
of adipocytes. Abnormal expression of SREBPs may have a
role in the pathogenesis of NAFLD. Indeed, SREBPs are
potential therapeutic targets for NAFLD [4, 5].
Schisandra is a traditional Chinese herbal remedy for
chemical- and virus-induced liver injury. Aqueous and
ethanolic extracts of Schisandra were recently shown to
have a significant lipid-lowering effect in mice models of
fatty liver [6]. Its active components and synthetic deriv-
atives such as, bifendate and bicyclol, also showed a
similar effect [7, 8]. The effect may be mediated via
downregulation of SREBP-1 expression. Moreover, anti-
oxidative, hypoglycemic and anti-inflammatory effects of
Schisandra have also been demonstrated [9]. Based on
these findings, a potential role of Schisandra in the treat-
ment of NAFLD is of considerable interest. The active
ingredients of Schisandra include lignans and polysac-
charides [10]; most studies till date have focused on the
ethanol extracts and lignans of Schisandra.
Pan et al. [11] reported that Schisandra B, the most
abundant and active dibenzocyclooctadiene derivative
isolated from the fruit of Schisandra chinensis, increased
serum and hepatic triglyceride levels in mice at a dose of
1 g/kg. Moreover, it was used to develop an experimen-
tal model of acute hypertriglycerdemia, which indicates
that lignans are not ideal for the treatment of NAFLD.
Plant polysaccharides have recently evoked consider-
able interest for their lipid-lowering, hypoglycemic, and
immunomodulatory properties. Our laboratory has been
involved in research on SCP since 2010 and our previous
studies revealed a hypolipidemic, anti-obesity and hepa-
toprotective effect of SCP against chemical-induced liver
injury in obese mice. The findings suggest SCP to be the
main component of Schisandra responsible for its lipid-
lowering and hepatoprotective effects.
In this study, a NAFLD mouse model was established by
feeding mice with a high-fat diet. Effects of Schisandra
polysaccharide on NAFLD were investigated, including its
effect on SREBPs and the related genes.
Methods
Reagents
Schisandra chinensis was purchased from Jilin Province,
Jian. Schisandra seedlings base was identified by Professor
Li-Hua Zhang at the College of Pharmacy, Beihua
University according to the identification standard of
the Pharmacopoeia of the People’s Republic of China
(2010 Edition). Kits for measurement of serum levels
of TG, TC, LDL-C, HDL-C, ALT, and AST were pur-
chased from BioSino Biotechnology & Science Inc.
(Beijing, China). Kits for measuring tissue TC and TG
were purchased from Applygen Technologies Inc.
(Beijing, China). Primers were synthesized by Dingguo
Changsheng Biotechnology Co. Ltd. (Beijing, China).
Polyclonal antibodies to SREBP-1c, SREBP-2, HMGCR,
LXRα, ACC, and FAS were purchased from Abcam
(London, England). Reagents for Western Blot and RT-PCR
were purchased from Sigma Aldrich.
Extraction and characterization of SCP
Extraction of SCP
SCP was prepared at the Jilin Province Schisandra
Industrialization and Engineering Research Center. Briefly,
lipid-soluble substances were removed by supercritical
CO2 extraction; the single factor test of SCP extraction
was used to determine the ratio of material to water (1:20,
1:30, and 1:40), extraction temperature (80 °C, 90 °C, and
100 °C) and extraction time (2, 3, and 4 h); orthogonal test
(L93
3) were used to determine the optimal conditions (the
ratio of material to water: 1:30; extraction temperature:
100 °C, and extraction time: 3 h). The concentrated ex-
tract was precipitated in about 5× volume of 95%
ethanol for 6 h, which was then centrifuged and dried to
obtain crude polysaccharides of Schisandra. The crude
polysaccharides were deproteinized by the enzymolysis
method combined with trichloroacetic acid-n-butanol
method, namely, enzyme 2%, pH 5.0, and enzymatic hy-
drolysis at 60 °C for 2 h, and then treated with an equal
volume of trichloroacetic acid-n-butanol solution for 5
times. Activated carbon was used for decolorization. The
optimum conditions were: 60 °C, pH 4.0, 1.5% activated
carbon, stirring for 50 min, and 91.7% decolorization rate.
The refined SCP obtained by the above methods was used
in animal experiments.
Characterization of SCP
Using D-glucose as the reference, the total sugar content
was determined by phenol-sulfuric acid method. Using
galacturonic acid as the reference, the uronic acid con-
tent was measured with meta-hydroxydiphenyl method.
The protein content was detected with Coomassie
brilliant blue method.
Animal experimentation
Male C57BL/6 mice, weighing 19–21 g, were provided
by Beijing Vital River Laboratory Animal Technology
Co. Ltd. (Beijing, China) [license number: SCXK
(Beijing) 2012–0001, SPF]. The mice were raised in
separate cages maintained at 18–22 °C (relative humidity
40–60%), under normal lighting conditions (lights on
from 7 a.m. to 7 p.m.), and with ad libitum access to
water. The normal (AIN-93) and high-fat diet (AIN-93
modified) for experimental mice was purchased from
Changchun City Yisi Laboratory Animal Technology Co.
Ltd (Changchun, Jilin, China) (Table 1). All procedures
were approved by the Ethics Committee for Use of
Experimental Animals at the Beihua University (Jilin,
China).
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Establishment of NAFLD model and drug administration
Twenty out of 40 male mice were randomly divided into
a normal control group (CON, n = 10) and a normal
control plus SCP (100 mg/kg) group (CON + SCP, n = 10),
and the mice were fed on the normal diet. The remaining
20 mice were used to establish NAFLD model. After being
fed on high-fat diet for 4 weeks, the mice were denied
food but not water for 12 h. Blood was collected from eye-
balls with a capillary glass tube and the serum total chol-
esterol and triglyceride levels measured to ascertain the
establishment of the model.
Subsequently, these mice were randomly divided into
NAFLD group (NAFLD) and NAFLD plus SCP (100
mg/kg) group (NAFLD + SCP), n = 10 in each group.
Mice in the CON and NAFLD groups were administered
equal volumes of water and those in the CON + SCP
and NAFLD + SCP groups were administered 100 mg/kg
SCP orally, once daily for 12 weeks. The dosage of SCP
used in this study was based on the pre experiment [12].
Body weights were measured every week. After the last
administration of water or SCP, all mice were denied
food but not water for 12 h, and anesthetized with ether,
then 0.8–1.0 mL of blood was collected from each
mouse by removing eyeballs. Serum was separated by
centrifugation and stored at −80 °C.
The peritoneal cavity was opened along the abdominal
middle line, and the liver carefully isolated and resected.
The liver index (wet liver weight/body weight × 100%),
overall morphology and the surface gloss of the liver was
documented. Hepatic tissue was washed with cold saline
and divided into three parts: the first part was fixed with
10% neutral formaldehyde for histopathological examin-
ation; the second part was prepared into homogenates
for estimation of liver lipids; and the third part was
preserved at −80 °C for studying the expression of
SREBPs and related genes.
Measurement of serum biochemical markers
TG, TC, LDL-C, and HDL-C levels in the serum were
detected using enzymatic methods as per manufacturer’s
instructions (BioSino Biotechnology & Science Inc.,
Beijing, China).
Measurement of hepatic lipid content
One hundred milligrams of liver tissue was cut into
pieces and placed in tubes containing 10% lysate buffer.
After being left to stand for 1h, the sample was homoge-
nized at 16,000 rpm in ice-water (the homogenization
process was repeated 3 times; the duration of each
homogenization process was 5 s, followed by a 3 s inter-
val). The homogenate was heated at 70 °C in a water bath
for 10 min and centrifuged twice at 3500 × g for 5 min
and the supernatant obtained. TC and TG content in the
supernatant was detected as per manufacturer’s instruc-
tions (Applygen Technologies Inc., Beijing, China).
Histopathological examination
Liver tissue sections were stained with hematoxylin-
eosin (H&E). The images were digitized by Nikon Digital
Camera attached with BH51 microscope (Olympus,
Tokyo, Japan). An experienced histopathologist blinded
to the treatment protocol evaluated the stained slides.
Each sample was observed at 100× magnification.
RNA extraction and real-time reverse transcription poly-
merase chain reaction
Total RNA was extracted from mouse liver tissues using
Trizol reagent (Invitrogen, USA) to examine the effects
of SCP on the expression of TG- and TC-related genes.
Reverse transcription (RT) of total RNA (1 μg) was per-
formed as per manufacturer’s instructions (Promega,
Beijing, China) in a final volume of 20 μL. PCR primer
sequences were designed using primer 6.0 software and
synthesized by Dingguo Changsheng Biotechnology Co.
Ltd (Beijing, China). The gene expression levels were
analyzed in duplicate using a SYBR Green kit (Promega,
Beijing, China), according to the manufacturer’s instruc-
tions, on real-time PCR System (ABI 7500, Biometra,
Germany). The primer lengths and annealing tempera-
tures are listed in Table 2. The ΔΔCt method was used
for relative quantification. The relative gene expression
was normalized to GAPDH expression, and the ratios
presented as arbitrary units.
Western blot analysis
Protein samples were prepared from liver tissues by
homogenization with ice-cold lysate buffer for 1 h, and
the tissue lysate samples centrifuged at 15,000 × g for 20
Table 1 Composition of experimental diet ND and HFD
Ingredients ND HFD
Corn Starch (%) 72.07 59.57
Casein (%) 14.0 14.0
Soybean Oil (%) 4.0 4.0
Lard (%) - 10.0
Sucrose (%) 5.0 5.0
Cholesterol (%) - 2.0
Sodium Taurocholate (%) - 0.5
Mixture of Vitamins (%) 1.0 1.0
Mixture of Mineral (%) 3.5 3.5
L-cystine (%) 0.18 0.18
Choline Bitartrate (%) 0.25 0.25
Hydroquinone (g/kg) 0.008 0.008
Energe (Kal/kg) 3802 5443
ND normal diet, HFD high-fat diet
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min at 4 °C. The supernatants were collected and the
protein concentrations measured using Bradford assay
(Bio-rad protein assay kit). For detection of SREBP-1c,
SREBP-2, FAS, ACC, HMGCR and LXRα protein
expressions, protein samples (60–80 μg) were denatured
by boiling for 5 min, separated by 10% SDS-
polyacrylamide gel, electroblotted at 4 °C and transferred
onto polyvinylirdene diflouride (PVDF) membranes
(Millipore, USA). The membranes were blocked in 5%
non-fat milk for 2 h at room temperature and then incu-
bated with rabbit polyclonal antibodies against SREBP-
1c, SREBP-2, FAS, ACC, HMGCR and LXRα (diluted
1:1,000) with gentle agitation overnight at 4 °C. The
membranes were washed 3 times for 10 min each with
15 mL of TBST and then incubated with second anti-
body (1:1000 goat Anti-rabbit IgG Horseradish Peroxid-
ase Conjugate (Santacruz Biotechnology) at room
temperature for 2 h. The protein was then visualized
using an enhanced chemiluminescence solution and
Kodak X-ray film. An imaging densitometer was used to
scan the protein bands; quantification was performed
using the Image Analysis Software.
Statistical analysis
All data are expressed as mean ± Standard Deviation. “n”
denotes the sample size in each group. Between-group
differences were assessed using one-way Analysis of
Variance (ANOVA) with post hoc test for multiple com-
parisons. SPSS software (version 20.0 for Windows) was




SCP was in a milky white powder form and its yield was
10.62% (the percentage of SCP to the dry weight of raw
medicinal material). The total sugar content, uronic acid
content and protein content of SCP were 68.2%, 2.96%,
and 0.71 mg/g, respectively.
Effects of SCP on the liver weight and liver index
At 12 weeks, liver weights in the NAFLD group were in-
creased by 30.5% as compared to that in the control
mice (P < 0.05). However, no significant difference was
observed with respect to body weight, which may reflect
the effect of sodium taurocholate on the appetite of mice
[13]. The liver weight and liver index were reduced by
15.3% and 12.0%, respectively, in NAFLD + SCP group
when compared with NAFLD group (P < 0.05) (Table 3).
Effects of SCP on blood lipid levels
As shown in Table 4, compared with those in CON
group, serum TC, TG and LDL-C levels in the NAFLD
group were increased by 100.3%, 72.9%, and 138.9%, re-
spectively (P < 0.01 or P < 0.05), while serum HDL-C
levels were decreased by 32.9% (P < 0.05). As compared
to that in NAFLD group, the serum TC, TG and LDL-C
levels in NAFLD + SCP group were decreased by 28.3%,
31.3% and 42.8%, respectively (P < 0.05), while serum
HDL-C levels were increased by 26.9% (P < 0.05), which
indicates alleviation of dyslipidemia in NAFLD mice by
SCP. No effect of SCP on blood lipid levels was observed
in control mice.
Effects of SCP on the accumulation of hepatic lipids
Histopathological examination of liver tissues showed a
normal intact structure of hepatic lobules, round shape of
liver cells, central location of nuclei, pink dyeing of the
cytoplasm, and normal structure of portal area around
hepatic lobules in the CON group (Fig. 1a-CON). In the
NAFLD group, the structural disorder of hepatic lobules,
dilation of portal area-central vein, fatty degeneration of
Table 2 Primers used for quantitative real-time polymerase
chain reaction
Genes Primer sequences Length
SREBP-1c Forward 5′-GGAGACATCGCAAACAAGC-3′ 273bp
Reverse 5′-GGTAGACAACAGCCGCATC-3′
SREBP-2 Forward 5′-CACCCATACTCAGGCTCG-3′ 133bp
Reverse 5′-GCTTCACAAAGACGCTCAA-3′
FAS Forward 5′-ATCGCCTATGGTTGTTG-3′ 127bp
Reverse 5′-TCACGACTGGAGGTTCTA-3′
ACC Forward 5′-TATCCCAACTCTTCCCTG-3′ 116bp
Reverse 5′-CCTTCACATAGCCTTTCTC-3′
HMGCR Forward 5′-CTTGACGCTCTTGTGGA-3′ 259bp
Reverse 5′-CCCTTTGGGTTACGG-3′
LDLR Forward 5′-GGAGGTGACCAACAATAGAA-3′ 190bp
Reverse 5′-TACGCTGCCTGGGACTG-3′
LXR Forward 5′-CTCAATGCCTGATGTTTCTCC-3′ 154bp
Reverse 5′-TGACTCCAACCCTATCCCTAA-3′
Table 3 Effects of SCP on body weight, liver weight and liver







CON 29.57 ± 2.25 1.05 ± 0.18 3.52 ± 0.85
CON + SCP 28.94 ± 1.84 1.02 ± 0.14 3.47 ± 0.68
NAFLD 30.52 ± 2.34 1.37 ± 0.11* 4.58 ± 0.60*
NAFLD + SCP 28.56 ± 1.97 1.16 ± 0.19# 4.03 ± 0.71#
CON: treated with saline 0.1 mL/10g; NAFLD: treated with saline 0.1 mL/10g;
CON + SCP and NAFLD + SCP: treated with SCP (100 mg/kg). Data are expressed
as mean ± SD (n = 10) and analyzed using one-way ANOVA with post hoc test
SCP Schisandra polysaccharide, NAFLD non-alcoholic fatty liver disease, SD standard
deviation, ANOVA, analysis of variance
*P < 0.05 vs. CON and CON + SCP groups; #P < 0.05 vs. model group
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liver cells within hepatic lobules, mixed fatty degeneration
characterized by macrovesicular steatosis, enlargement of
liver cell volume, visible cavitation within the cytoplasm,
and hepatocellular spotty necrosis within hepatic lobules
was noted (Fig. 1a-NAFLD). Compared with NAFLD
group, a relatively normal structure of hepatic lobules, sig-
nificantly improved fatty degeneration of liver cells in hep-
atic lobules and less visible necrosis of hepatocytes was
noted in NAFLD+ SCP group (Fig. 1a-NAFLD+ SCP).
The TC and TG content in liver tissue of mice in NAFLD
group were significantly increased by 41.4% and 77.1%, re-
spectively (P < 0.05) when compared with those in CON
group. While TC and TG content of liver tissue in
NAFLD + SCP group was significantly reduced by 27.0%
and 28.3%, respectively, when compared to NAFLD group
(P < 0.05), which indicates that SCP could improve lipid
accumulation in the liver tissue and protect the liver cells
(Fig. 1b).
Effects of SCP on serum aminotransferase levels
ALT and AST levels are considered as “gold standard”
markers of hepatic cell injury. The results showed that
compared with those in CON group, serum ALT and
AST levels of mice were elevated by 20.2 and 15.6%,
respectively (P < 0.05), in the NAFLD group, while the
levels were reduced by 20.1 and 15.5%, respectively
(P < 0.05), in the NAFLD + SCP group as compared to
those in the NAFLD group. These findings suggest a
hepatoprotective effect of SCP (Fig. 2).
Effects of SCP on mRNA and protein expressions of genes
coding for SREBPs
As shown in Figs. 3 and 4, mRNA and protein expres-
sion levels of hepatic lipogenesis genes such as SREBP-
1c, FAS, and ACC, were found to be increased in the
NAFLD mice. Treatment with SCP inhibited the mRNA
and protein expression levels. Furthermore, mRNA
expression levels of LXRα, which can activate the tran-
scription factor, SREBP-1c, were significantly decreased
in the NAFLD + SCP group. In addition, the expression
levels of SREBP-2 and HMGCR, which are key regula-
tory factors for cholesterol synthesis in the liver, were
significantly increased in the NAFLD mice. The expres-
sion of SREBP-2 and HMGCR was significantly
decreased in the NAFLD + SCP group. These data









CON 2.89 ± 0.26 0.85 ± 0.11 0.90 ± 0.05 1.58 ± 0.54
CON + SCP 2.85 ± 0.45 0.88 ± 0.25 0.84 ± 0.08 1.53 ± 0.32
NAFLD 5.79 ± 0.70** 1. 47 ± 0.31* 2.15 ± 0.61** 1.06 ± 0.21*
NAFLD + SCP 4.15 ± 0.86# 1.01 ± 0.21# 1.23 ± 0.24# 1.45 ± 0.38#
CON: treated with saline 0.1 mL/10g; NAFLD: treated with saline 0.1 mL/10g;
CON + SCP and NAFLD + SCP: treated with SCP (100 mg/kg). Data are
expressed as mean ± Standard deviation (n = 10) and analyzed using one-way
ANOVA with post hoc test. *P < 0.05, **P < 0.01 vs. CON and CON + SCP group;
#P < 0.05,##P < 0.01 vs. model group
SCP Schisandra polysaccharide, NAFLD non-alcoholic fatty liver disease, TG
triglycerides, TC, total cholesterol, LDL-C, low-density lipoprotein cholesterol,
SD standard deviation, ANOVA, analysis of variance
Fig. 1 Effects of SCP on the pathomorphology of liver and hepatic lipid content in NAFLD mice. a H&E stained sections of liver tissue (×100);
b Quantitative analysis of hepatic total cholesterol (TC) and triglyceride (TG) content. Mice in SCP group were administered SCP at 100 mg/kg/
day for 12 weeks. Data are expressed as means ± SD (n = 10). Between-group differences were assessed using one-way ANOVA with post hoc test.
*P < 0.05 vs. CON and CON + SCP groups; # P < 0.05 vs. model group. SCP, Schisandra polysaccharide; NAFLD, non-alcoholic fatty liver disease; H&E,
hematoxylin and eosin; SD, standard deviation; ANOVA, analysis of variance
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Fig. 3 Effects of SCP on the mRNA expressions of lipogenic and cholesterol-related synthetic enzymes. a mRNA expressions of lipogenic enzymes (LXRα,
SREBP-1c, FAS, and ACC) in the liver of mice were suppressed by SCP (100 mg/kg/day); bmRNA expressions of cholesterol-related synthetic enzymes
(SREBP-2 and HMGCR) in the liver was suppressed by SCP-100 mg/kg/day. All data are expressed as mean (± SD) (n = 10) from three independent
experiments; Between-group differences were assessed using one-way ANOVA with post hoc test. **P < 0.01, *P < 0.05 vs. CON and CON+ SCP groups;
##P < 0.01, #P< 0.05 vs. model group. SCP, Schisandra polysaccharide; NAFLD, non-alcoholic fatty liver disease; SD, standard deviation; ANOVA, analysis of variance
Fig. 2 Effects of SCP on serum aminotransferases in NAFLD mice. Mice in SCP group were administered SCP (100 mg/kg/day) for 12 weeks. Data are
expressed as means ± SD (n= 10); Between-group differences were assessed using one-way ANOVA with post hoc test. *P< 0.05 vs. CON and CON+ SCP
groups; # P< 0.05 vs. model group. SCP, Schisandra polysaccharide; NAFLD, non-alcoholic fatty liver disease; SD, standard deviation; ANOVA, analysis of variance
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strongly suggest improved hepatic lipid metabolism after
treatment with SCP.
Discussion
Schisandra is the dried ripe fruit of Schisandra chinensis
(Turcz.) Baill, a Schisandraceae plant, initially recorded
in Shen Nong’s Materia Medica and classified as a top
grade. It has long been known as the “king of protecting
liver” on account of its hepatoprotective effects. Polysac-
charides are the main active constituent of Schisandra
and its content accounts for about 10%.
Effects of a refined SCP were observed in mice with
NAFLD. The results showed that SCP could significantly
reduce the liver index, decrease the serum levels of ami-
notransferases, triglycerides, cholesterol and low-density
lipoprotein cholesterol, increase the serum level of high-
density lipoprotein cholesterol, lower the content of
triglycerides and cholesterol in the liver tissue, and
ameliorate lipid accumulation and fatty degeneration of
hepatocytes in NAFLD mice.
Pathogenesis of NAFLD is complex; the “two-hit hy-
pothesis” suggests that the excessive accumulation of
lipids induced by disordered lipid metabolic in liver cells
is a prerequisite for the development of NAFLD [14].
ACC and FAS, the key enzymes for the synthesis of fatty
acids in the liver, are regulated by nuclear transcription
factor SREBP-1c [15]. Studies have shown that the
hepatic expression of SREBP-1c and its target lipid syn-
thesis regulation genes, FAS and ACC, increase several
times both in patients with NAFLD and in animal
models such as transgenic mice, ob/ob mice (leptin defi-
ciency results in an insulin resistance and hyperinsuline-
mia), and high-fat diet-fed mice and rats, which leads to
deposition of a large amount of TG [16–20].
Gene expression of SREBP-1c is regulated by LXRα, a
nuclear receptor; activation of LXRα increases the
expression of SREBP-1c, FAS, and ACC, which results in
increased deposition of TGs in the liver [21]. In animal
models and patients with NAFLD, the expression of
LXRα/SREBP-1c significantly increases and shows strong
positive correlation [22]. Consistent with these reports,
our results showed that hepatic expression of LXRα, and
SREBP-1 were significantly increased in the liver of
NAFLD mice, and that SCP down-regulated the expres-
sion of LXRα and SREBP-1c.
Furthermore, SCP could significantly reduce the
expression of SREBP-2 and HMGCR in NAFLD mice. In
recent years, the role of abnormal cholesterol metabol-
ism in the pathogenesis of NAFLD has attracted wide
attention [23]. In 2007, Puri et al. [24] reported a signifi-
cant increase in free cholesterol in the liver of patients
with NAFLD. Caballero et al. [25] verified that in
patients with NAFLD, not only free cholesterol but also
SREBP-2 levels increased significantly. Furthermore,
Fig. 4 Effects of SCP on protein expression of lipogenic and cholesterol-related synthetic enzymes. a Protein expression of lipogenic enzymes (SREBP-1c,
FAS, and ACC) in the liver of mice was suppressed by SCP-100 mg/kg/day; b The protein expression of cholesterol-related synthetic enzymes (SREBP-2 and
HMGCR) in the liver of mice was suppressed by SCP-100 mg/kg/day. The protein levels are expressed relative to GAPDH. All data are expressed as mean
(± SD) (n= 10) of three independent experiments; Between-group differences were assessed using one-way ANOVA with post hoc test. *P< 0.05 vs. CON
and CON+ SCP groups; # P< 0.05 vs. model group. SCP, Schisandra polysaccharide; SD, standard deviation; ANOVA, analysis of variance
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accumulated cholesterol is oxidized to cholesterol
oxides, which further aggravates fat accumulation in
liver cells via activation of LXRα/SREBP-1c pathway and
upregulation of fatty acid and triglyceride synthesis [26, 27].
Our results suggest that SCP may alleviate the toxicity due
to cholesterol accumulation in the mouse model of NAFLD
induced by high-fat diet.
In China, Schisandra is listed as a raw material for
nutraceuticals. Studies have shown that functional food
and nutraceuticals have the potential to become the
future of primary prevention and treatment of dyslipi-
daemia in particular, and cardiovascular disease preven-
tion, in general [28]. The hepatoprotective and
hypolipidemic effect of Schisandra makes it a promising
candidate for development as a possible nutraceutical.
Conclusion
In this study, SCP, an active component of Schisandra,
improved liver function and alleviated fatty degener-
ation in the liver in NAFLD mice, an effect which
appears to be mediated via down-regulation of LXRα/
SREBP-1c/FAS/ACC and SREBP-2/HMGCR signaling
pathways in the liver. These results provide a theoret-
ical basis for further development and application of
Schisandra.
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